Areas of Research

1. Mek5/ERK5 pathway in cancer

(i) We are analyzing the tumorigenic capacity of ERK5 in the breast by generating an animal model of expression of MEK5DD (the constitutively active form of MEK5) in the breast epithelia.

(ii) We intend to identify genes regulated by either gain or loss-offunction of ERK5, by using several cellular models.

(iii) We are investigating the participation of ERK5 in the proliferation of triple negative breast cancer cells, as we have also observed increased levels of ERK5 in this subtype of breast cancer.

2. Therapies directed against ERK5

Because ERK5 pathway could represent a new therapeutic target, we aim to:

(i) study the efficiency, in breast cancer, of an inhibitor directed against ERK5, designed by an US-based company

(ii) identify proteins that are associated with ERK5.

Projects

• Instituto de Salud Carlos III (2016-2018)

  La ruta de MEK5/ERK5 como diana terapéutica en cáncer

• Junta de Castilla y León (2010-2010)

  Identificación de nuevos componenetes de lavía de Erk5, y terapias dirigidas contra esta quinasa

• Fundación Samuel Solórzano Barruso (2010-2010)

  La ruta de MEK5/Erk5 en cáncer

• Instituto de Salud Carlos III (2010-2013)

  La ruta de ERK5 en cáncer

• Junta de Castilla y León (2008-2008)

  “Quinasas en cáncer de mama con fenotipo basal”

• Instituto de Salud Carlos III (2007-2009)

  LA RUTA DE MEK5/ERK5 EN CANCER DE MAMA

• Junta de Castilla y Leon (2006-2008)

  La ruta de MEK5/ERK5 en cáncer de mama

• Junta de Castilla y León (2006-2006)

  La vía de transducción de señales ERK5 en pacientes con cáncer de mama

• INSTITUTO DE SALUD DE CARLOS III (2005-2008)

  Neuregulinas, receptores ERBB, y señalización por ERK5 en cáncer

NCBI-PubMed Articles

Publications

(*) Means equal contribution as senior authors.

2024

ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression.

Guillén-Pérez YM, Ortiz-Ruiz MJ, Márquez J, Pandiella A, Esparís-Ogando A, 
Int J Mol Sci; 2024; 25(6); 3273; 38542254

2023

Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications.

Sánchez-Fdez A, Matilla-Almazán S, Del Carmen S, Abad M, Arconada-Luque E, Jiménez-Suárez J, Chinchilla-Tábora LM, Ruíz-Hidalgo MJ, Sánchez-Prieto R, Pandiella A, Esparís-Ogando A, 
Exp Mol Med; 2023; 55(6); 1247-1257; 37332046

2020

Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.

Nieto-Jimenez C, Galan-Moya EM, Corrales-Sanchez V, Noblejas-Lopez MDM, Burgos M, Domingo B, Montero JC, Gomez-Juarez M, Picazo-Martinez MG, Esparís-Ogando A, Pandiella A, Ocaña A, 
Cancer Lett; 2020; 491(); 50-59; 32735909

2019

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors.

Pérez-Pena J, Tibor Fekete J, Páez R, Baliu-Piqué M, García-Saenz JA, García-Barberán V, Manzano A, Pérez-Segura P, Esparís-Ogando A, Pandiella A, Győrffy B, Ocana A, 
Front Immunol; 2019; 10(); 2802; 31921107

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.

Noblejas-Lopez MDM, Nieto-Jimenez C, Burgos M, Gomez-Juarez M, Montero JC, Esparís-Ogando A, Pandiella A, Galan-Moya EM, Ocaña A, 
J Exp Clin Cancer Res; 2019; 38(1); 383; 31470872

MEK5 promotes lung adenocarcinoma.

Sánchez-Fdez A, Ortiz-Ruiz MJ, Re-Louhau MF, Ramos I, Blanco-Múñez Ó, Ludeña D, Abad M, Sánchez-Martín M, Pandiella A, Esparís-Ogando A, 
Eur Respir J; 2019; 53(2); 1801327; 30442718

2017

ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA.

Talamillo A, Grande L, Ruiz-Ontañon P, Velasquez C, Mollinedo P, Torices S, Sanchez-Gomez P, Aznar A, Esparís-Ogando A, Lopez-Lopez C, Lafita C, Berciano MT, Montero JA, Vazquez-Barquero A, Segura V, Villagra NT, Pandiella A, Lafarga M, León J, Martínez-Climent JA, Sanz-Moreno V, Fernandez-Luna JL, 
Oncogene; 2017; 36(12); 1733-174; 27641332

2016

Targeting the EGF/HER Ligand-Receptor System in Cancer.

Esparís-Ogando A, Montero JC, Arribas J, Ocaña A, Pandiella A, 
Curr. Pharm. Des.; 2016; 22(39); 5887-589; 27426127

Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies.

Ocaña A, Díez-González L, Esparís-Ogando A, Montero JC, Amir E, Pandiella A, 
Oncotarget; 2016; 7(29); 45042-45; 27074567

2015

The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma.

Rovida E, Di Maira G, Tusa I, Cannito S, Paternostro C, Navari N, Vivoli E, Deng X, Gray NS, Esparís-Ogando A, David E, Pandiella A, Dello Sbarba P, Parola M, Marra F, 
Gut; 2015; 64(9); 1454-65; 25183205

2014

Therapeutic potential of ERK5 targeting in triple negative breast cancer.

Ortiz-Ruiz MJ, Alvarez-Fernández S, Parrott T, Zaknoen S, Burrows FJ, Ocaña A, Pandiella A, Esparís-Ogando A, 
Oncotarget; 2014; 5(22); 11308-18; 25350956

Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.

Montero JC, Esparís-Ogando A, Re-Louhau MF, Seoane S, Abad M, Calero R, Ocaña A, Pandiella A, 
Oncogene; 2014; 33(2); 148-56; 23246963

2013

ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.

Arias-González L, Moreno-Gimeno I, del Campo AR, Serrano-Oviedo L, Valero ML, Esparís-Ogando A, de la Cruz-Morcillo MA, Melgar-Rojas P, García-Cano J, Cimas FJ, Hidalgo MJ, Prado A, Callejas-Valera JL, Nam-Cha SH, Giménez-Bachs JM, Salinas-Sánchez AS, Pandiella A, del Peso L, Sánchez-Prieto R, 
Neoplasia; 2013; 15(6); 649-59; 23730213

Potent antimyeloma activity of a novel ERK5/CDK inhibitor.

Alvarez-Fernández S, Ortiz-Ruiz MJ, Parrott T, Zaknoen S, Ocio EM, San Miguel J, Burrows FJ, Esparís-Ogando A, Pandiella A, 
Clin. Cancer Res.; 2013; 19(10); 2677-87; 23532886

Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue.

Ruiz-Ontañon P, Orgaz JL, Aldaz B, Elosegui-Artola A, Martino J, Berciano MT, Montero JA, Grande L, Nogueira L, Diaz-Moralli S, Esparís-Ogando A, Vazquez-Barquero A, Lafarga M, Pandiella A, Cascante M, Segura V, Martínez-Climent JA, Sanz-Moreno V, Fernandez-Luna JL, 
Stem Cells; 2013; 31(6); 1075-85; 23401361

2009

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.

Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-González L, Esparís-Ogando A, del Peso Ovalle L, Bellón-Echeverria I, de la Cruz-Morcillo MA, Galán Moya EM, Moreno Gimeno I, Gómez JC, Deininger MW, Pandiella A, Sánchez Prieto R, 
PLoS ONE; 2009; 4(7); e6124; 19568437

Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target.

Montero JC, Ocaña A, Abad M, Ortiz-Ruiz MJ, Pandiella A, Esparís-Ogando A, 
PLoS ONE; 2009; 4(5); e5565; 19440538

2008

Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.

Esparís-Ogando A, Ocaña A, Rodríguez-Barrueco R, Ferreira L, Borges J, Pandiella A, 
Ann. Oncol.; 2008; 19(11); 1860-9; 18641009

The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation.

Dorado F, Velasco S, Esparís-Ogando A, Pericacho M, Pandiella A, Silva J, López-Novoa JM, Rodríguez-Barbero A, 
Nephrol. Dial. Transplant; 2008; 23(11); 3403-11; 18567890

Neuregulins and cancer.

Montero JC, Rodríguez-Barrueco R, Ocaña A, Díaz-Rodríguez E, Esparís-Ogando A, Pandiella A, 
Clin. Cancer Res.; 2008; 14(11); 3237-41; 18519747

2007

Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer.

de Alava E, Ocaña A, Abad M, Montero JC, Esparís-Ogando A, Rodriguez CA, Otero AP, Hernández T, Cruz JJ, Pandiella A, 
J. Clin. Oncol.; 2007; 25(19); 2656-63; 17602072

Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis.

Borges J, Pandiella A, Esparís-Ogando A, 
Cell. Signal.; 2007; 19(7); 1473-87; 17317102

The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function.

Montero JC, Rodríguez-Barrueco R, Yuste L, Juanes PP, Borges J, Esparís-Ogando A, Pandiella A, 
Mol. Biol. Cell; 2007; 18(2); 380-93; 17108327

2005

Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.

Yuste L, Montero JC, Esparís-Ogando A, Pandiella A, 
Cancer Res.; 2005; 65(15); 6801-10; 16061662

Overexpression of RasN17 fails to neutralize endogenous Ras in MCF7 breast cancer cells.

Yuste L, Esparís-Ogando A, Santos E, Pandiella A, 
J. Biochem.; 2005; 137(6); 731-9; 16002995

Multifunctional role of Erk5 in multiple myeloma.

Carvajal-Vergara X, Tabera S, Montero JC, Esparís-Ogando A, López-Pérez R, Mateo G, Gutiérrez N, Parmo-Cabañas M, Teixidó J, San Miguel JF, Pandiella A, 
Blood; 2005; 105(11); 4492-9; 15692064

Bortezomib is an efficient agent in plasma cell leukemias.

Esparís-Ogando A, Alegre A, Aguado B, Mateo G, Gutiérrez N, Bladé J, Schenkein D, Pandiella A, San Miguel JF, 
Int. J. Cancer; 2005; 114(4); 665-7; 15609327

2002

Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated she

Díaz-Rodríguez E, Montero JC, Esparís-Ogando A, Yuste L, Pandiella A, 
Mol. Biol. Cell; 2002; 13(6); 2031-44; 12058067

Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases.

Montero JC, Yuste L, Díaz-Rodríguez E, Esparís-Ogando A, Pandiella A, 
Biochem. J.; 2002; 363(Pt 2); 211-21; 11931648

Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2.

Esparís-Ogando A, Díaz-Rodríguez E, Montero JC, Yuste L, Crespo P, Pandiella A, 
Mol. Cell. Biol.; 2002; 22(1); 270-85; 11739740

2000

Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme.

Montero JC, Yuste L, Díaz-Rodríguez E, Esparís-Ogando A, Pandiella A, 
Mol. Cell. Neurosci.; 2000; 16(5); 631-48; 11083924

Stimulation of cleavage of membrane proteins by calmodulin inhibitors.

Díaz-Rodríguez E, Esparís-Ogando A, Montero JC, Yuste L, Pandiella A, 
Biochem. J.; 2000; 346 Pt 2(); 359-67; 10677354

1999

Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase.

Esparís-Ogando A, Díaz-Rodríguez E, Pandiella A, 
Biochem. J.; 1999; 344 Pt 2(); 339-48; 10567214

Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms.

Díaz-Rodríguez E, Cabrera N, Esparís-Ogando A, Montero JC, Pandiella A, 
Eur J Neurosci; 1999; 11(4); 1421-30; 10103137

Patents

Group

• Azucena Esparís Ogando

  Azucena Esparís Ogando

  Mek5/ERK5 pathway in cancer. Therapies directed against ERK5.

  Telf.:

  Fax:

  Email: esparis@usal.es

  ---

  Contact

  ---

  Biography

  ×

---